Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding
Articolo
Data di Pubblicazione:
2021
Citazione:
Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding / Ciccullo, A; Borghi, V; Giacomelli, A; Cossu, M V; Sterrantino, G; Latini, A; Giacometti, A; De Vito, A; Gennari, W; Madeddu, G; Capetti, A; D'Ettorre, G; Mussini, C; Rusconi, S; Di Giambenedetto, S; Baldin, G. - In: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. - ISSN 1525-4135. - 88:3(2021), pp. 234-237. [10.1097/QAI.0000000000002787]
Abstract:
Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1 positive patients. We aimed to assess long-time efficacy and safety in our multicenter cohort.
Tipologia CRIS:
Articolo su rivista
Keywords:
dolutegravir; HAART; HIV; lamivudine;
Elenco autori:
Ciccullo, A; Borghi, V; Giacomelli, A; Cossu, M V; Sterrantino, G; Latini, A; Giacometti, A; De Vito, A; Gennari, W; Madeddu, G; Capetti, A; D'Ettorre, G; Mussini, C; Rusconi, S; Di Giambenedetto, S; Baldin, G
Link alla scheda completa:
Link al Full Text:
Pubblicato in: